Study of MRG003 for EGFR-positive advanced cancers
Part of Cancer clinical trials.
This trial tests a drug called MRG003 for people with certain advanced cancers that have a specific protein, EGFR. The drug targets the cancer cells that have this protein, which may help stop the cancer from growing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have an advanced or metastatic solid tumor that is EGFR-positive (like lung, head and neck, or nasopharyngeal cancer).
- You have at least one tumor that can be measured on a scan.
- You are generally healthy enough to be up and about (ECOG score 0 or 1).
- You have not had certain prior treatments or conditions that might be unsafe.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called MR001, which is designed to help your immune system fight cancer, in people with advanced solid tumors that have not responded to other treatments. It may be an option if standard treatments have stopped working or caused too many side effects.
This trial tests a new drug, MRG006A, for people with advanced solid tumors, especially liver cancer. It aims to see if the drug is safe and effective by targeting a protein called GPC3 found on some cancer cells.
This trial tests a new drug that targets a protein called MET found on some cancer cells. It may help people with certain advanced cancers that have not responded to other treatments.
This trial tests an investigational drug called MRG003 added to your current treatment for advanced thyroid cancer that has stopped responding. It may help people with specific types of thyroid cancer and certain tumor markers.
This study tests a new targeted drug (MRG003) combined with precise radiation (SBRT) for people with EGFR-positive solid tumors that have spread to a few new spots. The goal is to see if this combination works better than standard treatments to control the cancer.
This trial tests two drugs, MRG003 and HX008, as a first treatment for men with EGFR-positive penile squamous cell carcinoma that cannot be removed by surgery or has spread. The goal is to see if the combination shrinks tumors or delays growth.
Hear when a new Advanced Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.